TuHURA Biosciences (HURA) Non-Current Assets (2015 - 2026)
TuHURA Biosciences (HURA) posted quarterly Non-Current Assets of $22.7 million for Q1 2026, up 7152.7% year-over-year from $313297.0 in Q1 2025, and little changed quarter-over-quarter from $22.7 million in Q4 2025.
TuHURA Biosciences (HURA) Non-Current Assets (2015 - 2026) Analysis & Trends
TuHURA Biosciences' Non-Current Assets history runs 12 years deep, the most recent figure standing at $22.7 million for Q1 2026.
- In Q1 2026, Non-Current Assets rose 7152.7% year-over-year to $22.7 million; the TTM figure through Mar 2026 stood at $89.7 million (up 4385.15% YoY), while the FY2025 annual figure was $22.7 million, up 6280.11% from the prior year.
- Non-Current Assets for Q1 2026 stood at $22.7 million, roughly flat from $22.7 million in the prior quarter.
- The five-year high for Non-Current Assets was $22.7 million in Q4 2025, with the low at $202990.0 in Q4 2023.
- The 5-year median for Non-Current Assets is $724000.0 (2023), against an average of $6.2 million.
- The sharpest annual moves came in 2023 and 2026: Non-Current Assets sank 86.27% in 2023, then surged 7152.7% in 2026.
- TuHURA Biosciences' Non-Current Assets stood at $739000.0 in 2022, then slumped by 72.53% to $202990.0 in 2023, then soared by 75.52% to $356295.0 in 2024, then surged by 6280.11% to $22.7 million in 2025, then decreased by 0.04% to $22.7 million in 2026.
- Business Quant data shows HURA's Non-Current Assets at $22.7 million in Q1 2026, $22.7 million in Q4 2025, and $22.2 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.96 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 5.15 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 1.96 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 938.60 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 6.80 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 468.65 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 18.06 Bn |
| 10 | TuHURA Biosciences | 37.61 Mn | 37.61 Mn | - | 30.09 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 22.72 Mn |
| Dec 31, 2025 | 22.73 Mn |
| Sep 30, 2025 | 22.19 Mn |
| Jun 30, 2025 | 22.08 Mn |
| Mar 31, 2025 | 313,297.00 |
| Dec 31, 2024 | 356,295.00 |
| Sep 30, 2024 | 657,000.00 |
| Jun 30, 2024 | 674,000.00 |
| Mar 31, 2024 | 691,000.00 |
| Dec 31, 2023 | 202,990.00 |
| Sep 30, 2023 | 694,000.00 |
| Jun 30, 2023 | 709,000.00 |
| Mar 31, 2023 | 724,000.00 |
| Dec 31, 2022 | 739,000.00 |
| Sep 30, 2022 | 5.05 Mn |
| Jun 30, 2022 | 2.69 Mn |
| Mar 31, 2022 | 2.71 Mn |
| Dec 31, 2021 | 2.72 Mn |
| Sep 30, 2021 | 2.24 Mn |
| Jun 30, 2021 | 1.75 Mn |